National Analysis of the Requirements and Implementation of State Prescription Drug Price Transparency Laws
- 30 May 2025
- journal article
- Published by Wiley in The Milbank Quarterly
Abstract
Policy Points: A total of 21 states have passed drug price transparency laws with the goals of creating accountability around drug pricing and facilitating the development of policy solutions to address high prices. These laws vary in design but often require manufacturers to report the wholesale acquisition cost of drugs above a certain threshold for new drugs or of drugs that undergo a price increase above a certain margin, along with other data such as the manufacturer's costs. Initial findings suggest these laws may have contributed toward informing policymaking based on newly available public information but do not appear to have affected drug prices.Keywords
This publication has 4 references indexed in Scilit:
- Drug pricing and transparency in Europe and the United States: what is it and how does it work?Expert Review of Pharmacoeconomics & Outcomes Research, 2024
- Healthcare price transparency in North America and EuropeBritish Journal of Radiology, 2023
- Evidence on the effectiveness of policies promoting price transparency - A systematic reviewHealth Policy, 2022
- Analysis of State-Level Drug Pricing Transparency Laws in the United StatesJAMA Network Open, 2019